Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced/Metastatic Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07514065
What this trial is testing

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer Patients
Tasly Pharmaceutical Group Co., Ltd 78
Testing effectiveness (Phase 2)Study completedNCT00001239
What this trial is testing

Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms
National Cancer Institute (NCI) 100
Large-scale testing (Phase 3)Active Not RecruitingNCT06396065
What this trial is testing

Phase III Study of AK112 for NSCLC Patients

Who this might be right for
Non-Squamous Non-small Cell Lung Cancer
Summit Therapeutics 420
Early research (Phase 1)Study completedNCT01032681
What this trial is testing

EMD 521873 in Advanced Solid Tumors, MTD Finding

Who this might be right for
Non-Hodgkin Lymphoma
Merck KGaA, Darmstadt, Germany 66
Testing effectiveness (Phase 2)Study completedNCT00080353
What this trial is testing

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Who this might be right for
Melanoma
National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)Study completedNCT02066675
What this trial is testing

Trabectedin First Line Therapy In Unfit Sarcoma Study

Who this might be right for
Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to ReceiveStandard Chemotherapy
Italian Sarcoma Group 24
Testing effectiveness (Phase 2)Study completedNCT00060944
What this trial is testing

Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Who this might be right for
LiposarcomaLeiomyosarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 271
Testing effectiveness (Phase 2)UnknownNCT03219775
What this trial is testing

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Who this might be right for
Transitional Cell CarcinomaAdvanced CancerMetastatic Cancer
AIO-Studien-gGmbH 169
Testing effectiveness (Phase 2)Looking for participantsNCT05498428
What this trial is testing

Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC 520
Early research (Phase 1)Study completedNCT00747734
What this trial is testing

MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Cancers
Genentech, Inc. 35
Testing effectiveness (Phase 2)WithdrawnNCT02747797
What this trial is testing

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Who this might be right for
Advanced Cancer
Teresa Helsten, MD
Early research (Phase 1)Study completedNCT01287520
What this trial is testing

LY2090314 in Patients With Advanced or Metastatic Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 41
Early research (Phase 1)Study completedNCT01139788
What this trial is testing

LY2624587 in Patients With Advanced Cancer

Who this might be right for
Metastatic Cancer
Eli Lilly and Company 56
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07811297
What this trial is testing

Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Who this might be right for
Endometrial NeoplasmsOvarian NeoplasmsSoft Tissue Sarcoma (STS)+1 more
Advenchen Pharmaceuticals, LLC. 138
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Early research (Phase 1)Ended earlyNCT00955942
What this trial is testing

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Who this might be right for
Lung CancerRadiation Toxicity
Abramson Cancer Center at Penn Medicine 48
Testing effectiveness (Phase 2)Study completedNCT03809013
What this trial is testing

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 64
Early research (Phase 1)Looking for participantsNCT07619313
What this trial is testing

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced CholangiocarcinomaLocally Advanced Pancreatic Adenocarcinoma+5 more
Jonsson Comprehensive Cancer Center 46
Next Page